Salvage radiotherapy following radical prostatectomy

World Journal of Urology

Volumn 21, Issue 4, 2003, Pages 243-252

  Catton, Charles ^a   Milosevic, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Radical prostatectomy; Salvage radiotherapy

Indexed keywords

HUMAN; MALE; METHODOLOGY; PROSTATE TUMOR; PROSTATECTOMY; RADIOTHERAPY; REVIEW; SALVAGE THERAPY;

HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; SALVAGE THERAPY;

EID: 1542389491     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-003-0360-1     Document Type: Article

References (73)

1. Abi-Aad A, Macfarlane M, Stein A, deKernion J (1992) Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound. J Urol 147:952-955
2. Amling C, Bergstralh E, Blute M, Slezak J, Zincke H (2001) Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 165:1146-1151
3. Anscher M, Clough R, Dodge R (2000) Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys 48:369-375
4. Bianco F, Grignon D, Sakr W, Shekarriz B, Upadhyay J, Dornelles E, Pontes J (2003) Radical prostatectomy with bladder neck preservation: impact of a positive margin. Eur Urol 43:461-466
5. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300
6. Caddeddu J, Partin A, DeWeese T, Walsh P (1998) Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 159:173-177
7. Catalona W, Smith D (1994) 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152:1837-1842
8. Catton C, Gospodarowicz M, Warde P, Panzarella T, Catton P, McLean M, Milosevic M (2001) Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol 59:51-60
9. Chawla A, Thakral H, Zietman A, Shipley W (2002) Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors. Urology 59:726-731
10. Cher M, Bianco FJ, Lam J, Davis L, Grignon D, Sakr W, Banerjee M, Pontes J, Wood DJ (1998) Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160:1387-1391
11. Choo R, Hruby G, Hong J, Bahk E, Hong E, Danjoux C, Morton G, DeBoer G (2002) (In)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 53:269-276
12. Coetzee L, Hars V, Paulson D (1996) Postoperative prostate-specific antigen as a prognostic indicator in patients with margin positive prostate cancer undergoing adjuvant radiotherapy after radical prostatectomy. Urology 47:232-235
13. Connolly J, Shinohara K, Presti JJ, Carroll P (1996) Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 47:225-231
14. Cox J, Gallagher M, Hammond E, Kaplan R, Schellhammer P (1997) Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Ocol 17:1155
15. Crane C, Rich T, Read P, Sanfilippo M, Gillenwater J, Kelly M (1997) Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int J Radiat Oncol Biol Phys 39:681-686
16. de la Taille A, Flam T, Thiounn N, Pontvert D, Saighi D, Zerbib M, Debre B (2002) Predictive factors of radiation therapy for patients with prostate specific antigen recurrence after radical prostatectomy. BJU Int 90:887-892
17. Do T, Parker R, Do C, Tran L, Do L, Dolkar D (1998) Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Cancer J Sci Am 4:324-330
18. Doherty A, Bower M, Smith G, Miano R, Mannion E, Mitchell H, Christmas T (2000) Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer 83:1432-1436
19. Duchesne G, Millar J, Moraga V, Rosenthal M, Royce P, Snow R (2003) What to do for prostate cancer patients with a rising PSA? - a survey of Australian practice. Int J Radiat Oncol Biol Phys 55:986-991
20. Egawa S, Matsumoto K, Suyama K, Soh S, Kuwao S, Iwamura M (1999) Limited suppression of prostate specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy. Urology 53:148-154
21. Elias S, Parker R, Gallardo D, Law J (1997) Adjuvant radiation therapy after radical prostatectomy for carcinoma of the prostate. Am J Clin Oncol 20:120-124
22. Foster L, Jajodia P, Fournier GJ, Shinohara K, Carroll P, Narayan P (1993) The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol 149:1024-1028
23. Freedland S, Sutler M, Dorey F, Aronson W (2003) Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology 61:365-369
24. Garg M, Tekyi-Mensah S, Bolton S, Velasco J, Pontes E, Wood Jr D, Porter A, Forman J (1998) Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology 51:998-1002
25. Grossfeld G, Chang J, Broering J, Miller D, Yu J, Flanders S, Henning J, Stier D, Carroll P (2000) Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the Capsure database. J Urol 163:1171-1177
26. Han M, Partin A, Pound C, Epstein J, Walsh P (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28:555-565
27. Hinkle G, Burgers J, Neal C, Texter J, Kahn D, Williams R, Maguire R, Rogers B, Olsen J, Badalament R (1998) Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 83:739-747
28. Jhaveri F, Zippe C, Klein E, Kupelian P (1999) Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology 54:884-890
29. Kahn D, Williams R, Haseman M, Reed N, Miller S, Gerstbrein J (1998) Radioimmunoscintigraphy with in-ill-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Ocol 16:284-289
30. Kane C, Amling C, Johnstone P, Pak N, Lance R, Thrasher J, Foley J, Riffenburgh R, Moul J (2003) Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61:607-611
31. Kausik S, Blute M, Sebo T, Leibovich B, Bergstralh E, Slezak J, Zincke H (2002) Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer 95:1215-1219
32. Koppie T, Grossfeld G, Nudell D, Weinberg V, Carroll P (2001) Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol 166:111-115
33. Kupelian P, Katcher J, Levin H, Klein E (1997) Stage t1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 37:1043-1052
34. Lassiter L, Eisenberger M (2002) The dilemma of patients with a rising PSA level after definitive local therapy for prostate cancer. Semin Urol Oncol 20:146-154
35. Lattouf J, Saad F (2003) Digital rectal exam following prostatectomy: is it still necessary with the use of PSA? Eur Urol 43:333-336
36. Lau W, Bergstralh E, Blute M, Slezak J, Zincke H (2002) Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol 167:117-122
37. Leventis A, Shariat S, Kattan M, Butler E, Wheeler T, Slawin K (2001) Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Ocol 19:1030-1039
38. Leventis A, Shariat S, Slawin K (2001) Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 219:432-439
39. Levesque P, Nieh P, Zinman L, Seldin D, Libertino J (1998) Radiolabeled monoclonal antibody indium 111-labeled cyt-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology 51:978-984
40. Lightner D, Lange P, Reddy P, Moore L (1990) Prostate specific antigen and local recurrence after radical prostatectomy. J Urol 144:921-926
41. Mathews D, Oz O (2002) Positron emission tomography in prostate and renal cell carcinoma. Curr Opin Urol 12:381-385
42. Morris M, Dallow K, Zietman A, Park J, Althausen A, Heney N, Shipley W (1997) Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 38:731-736
43. Nudell D, Grossfeld G, Weinberg V, Roach 3rd M, Carroll P (1999) Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 54:1049-1057
44. Ornstein D, Colberg J, Virgo K, Chan D, Johnson E, Oh J, Johnson F (1998) Evaluation and management of men whose radical prostatectomies failed: results of an international survey. Urology 52:1047-1054
45. Parker C, Warde P, Catton C (2001) Salvage radiotherapy for PSA failure after radical prostatectomy. Radiother Oncol 61:107-116
46. Partin A, Pearson J, Landis P, Carter H, Pound C, Clemens J, Epstein J, Walsh P (1994) Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43:649-659
47. Patel A, Dorey F, Franklin J, deKernion J (1997) Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158:1441-1445
48. Petrovich Z, Lieskovsky G, Langholz B, Bochner B, Formenti S, Streeter O, Skinner D (1999) Adjuvant radiotherapy in patients with pathologic stage c (pT3N0) adenocarcinoma of the prostate. Urology 53:1184-1193
49. Pisansky T, Kozelsky T, Myers R, Hillman D, Blute M, Buskirk S, Cheville J, Ferrigni R, Schild S (2000) Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 163:845-850
50. Pollack A, Zagars G, Smith L, Lee J, von Eschenbach A, Antolak J, Starkschall G, Rosen I (2000) Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18:3904-3911
51. Pound C, Christens-Barry O, Gurganus R, Partin A, Walsh P (1999) Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J Urol 162:1337-1340
52. Pound C, Partin A, Eisenberger M, Chan D, Pearson J, Walsh P (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597
53. Price D, Coleman R, Liao R, Robertson C, Polascik T, DeGrado TR (2002) Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168:273-280
54. Ravery V (1999) The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Semin Urol Oncol 17:127-129
55. Salminen E, Hogg A, Binns D, Frydenberg M, Hicks R (2002) Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol 41:41
56. Scattoni V, Roscigno M, Raber M, Montorsi F, Bertini R, Bua L, Da Pozzo L, Rigatti P (2002) Diagnostic value of ultrasound-guided anastomotic biopsies in patients with high PSA ( > or = 0,4 nc/ml) after radical prostatectomy. Arch Ital Urol Androl 74:129-131
57. Scherr D, Swindle P, Scardino P (2003) National comprehensive cancer network guidelines for the management of prostate cancer. Urology 61 [Suppl 1]:14-24
58. Schild S, Wong W, Grado G, Buskirk S, Robinow J, Frick L, Ferrigini R (1994) Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin Proc 69:613-619
59. Schild S, Wong W, Grado G, Halyard M, Novicki D, Swanson S, Larson T, Ferrigni R (1996) The results of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys 34:535-541
60. Seltzer M, Barbaric Z, Belldegrun A, Naitoh J, Dorey F, Phelps M, Gambhir S, Hoh C (1999) Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 162:1322-1328
61. Shah R, Bassily N, Wei J, Mucci N, Montie J, Sanda M, Rubin M (2002) Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors. Urology 56:721-725
62. Sodee D, Malguria N, Faulhaber P, Resnick M, Albert J, Bakale G (2000) Multicenter Prostascint imaging findings in 2154 patients with prostate cancer. The Prostascint Imaging Centers. Urology 56:988-993
63. Song D, Thompson T, Ramakrishnan V, Harrison R, Bhavsar N, Onaodowan O, DeWeese T (2002) Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 60:281-287
64. Syndikus I, Pickles T, Kostashuk E, Sullivan L (1996) Post-operative radiotherapy for stage pT3 carcinoma of the prostate: Improved local control. J Urol 155:1983-1986
65. Trapasso J, deKernion J, Smith R, Dorey F (1994) The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152:1821-1825
66. Connolly J, Shinohara, K, Presti, JC Jr, Carroll, PR (1996) Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 47:225-231
67. Valicenti R, Gomella L, Ismail M, Mulholland S, Petersen R, Corn B (1998) Effect of higher radiation dose on biochemical control after radical prostatectomy for pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 42:501-506
68. Vanuytsel L, Janssens G, Van Poppel H, Rijnders A, Baert L (2001) Radiotherapy for PSA recurrence after radical prostatectomy. Eur Urol 39:425-429
69. Vicini F, Ziaja EL, Kestin LL, Brabbins DS, Stromberg JS, Gonzalez JA, Martinez, AA (1999) Treatment outcome with adjuvant and salvage radiation after radical prostatectomy for prostate cancer. Urology 54:111-117
70. 111In-labelled monoclonal antibody. Prostate 18:229-241
71. Yu H, Diamandis E, Wong P, Nam R, Trachtenberg J (1997) Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microg./l. J Urol 157:913-918
72. Zelefsky M, Aschkenasy E, Kelsen S, Leibel S (1997) Tolerance and early outcome of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 39:327-333
73. Zelefsky M, Fuks Z, Hunt M, Yamada Y, Marion C, Ling C, Amols H, Venkatraman E, Leibel S (2002) High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111-1116